Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Global Multicenter Phase 1/2 Trial of EO2463, a Novel Microbial-Derived Peptide Therapeutic Vaccine, as Monotherapy, and in Combination With Lenalidomide and Rituximab, for Treatment of Patients With Indolent Non-Hodgkin's Lymphoma

Next Previous
Trial Profile

A Global Multicenter Phase 1/2 Trial of EO2463, a Novel Microbial-Derived Peptide Therapeutic Vaccine, as Monotherapy, and in Combination With Lenalidomide and Rituximab, for Treatment of Patients With Indolent Non-Hodgkin's Lymphoma

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EO 2463 (Primary) ; Lenalidomide (Primary) ; Rituximab (Primary) ; Montanide ISA-51
  • Indications Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Acronyms SIDNEY
  • Sponsors Enterome

Most Recent Events

  • 09 Dec 2025 According to Enterome Media Release, data from this trial were presented at the 67th meeting of the American Society for Hematology (ASH) in Orlando, Florida.
  • 09 Dec 2025 Results presented at Enterome Media Release,
  • 13 Nov 2025 According to Enterome Media Release, company will present the next update on both sets of data at the 67th American Society of Hematology (ASH) meeting in Orlando, Florida, in December.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top